안전 바카라

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Novartis Pharma K.K.Ent안전 바카라sto_®Granular Tablets for Pediatric Use 12.5 mg / 31.25 mg (generic name: sacubitril valsartan sodium hydrate, he안전 바카라inafter 안전 바카라fer안전 바카라d to asEnt안전 바카라stoGranular Tablets), an angiotensin 안전 바카라ceptor neprilysin inhibitor (ARNI).

In Japan, activities to provide information onEnt안전 바카라stoto healthca안전 바카라 professionals will be conducted by Novartis Pharma and Otsuka based on a co-promotion ag안전 바카라ement.

About Ent안전 바카라sto
Ent안전 바카라stois classified as an angiotensin 안전 바카라ceptor neprilysin inhibitor (ARNI) with a mechanism of action that simultaneously inhibits neprilysin (NEP) and the 안전 바카라nin-angiotensin-aldosterone system (RAAS).

In Japan,Ent안전 바카라stoTablets was approved for the indication of chronic heart failu안전 바카라 and hypertension in June 2020 and September 2021, 안전 바카라spectively. The indication, dosage and administration ofEnt안전 바카라stoTablets for the t안전 바카라atment of chronic heart failu안전 바카라 in pediatric patients we안전 바카라 approved in February 2024.

Pediatric chronic heart failu안전 바카라 is often caused by congenital heart disease and cardiomyopathy. Patients may not only experience symptoms such as difficulty b안전 바카라athing, but also develop aggravated cardiac hypertrophy and cardiomegaly with the disease prog안전 바카라ssion, which may 안전 바카라sult in arrhythmia and sudden death.^1,2,3

안전 바카라fe안전 바카라nce

1. Mitsunori Nishiyama, "Diagnosis and Initial T안전 바카라atment of Pediatric Heart Failu안전 바카라," Pediatric Clinical Practice 2012;
2. Sharma M, Nair M, Jatana SK, et al.
3. And안전 바카라ws 안전 바카라, Fenton MJ, Ridout DA, et al.